Tilray Brands Reports Record Q3 Revenue and Gross Profit, Significantly Reduces Net Loss
summarizeSummary
Tilray Brands reported record Q3 fiscal 2026 net revenue and gross profit, with a substantial 97% reduction in net loss, and reconfirmed its full-year adjusted EBITDA guidance.
check_boxKey Events
-
Record Q3 Financial Performance
Net revenue increased 11% year-over-year to a record $206.7 million, and gross profit rose 6% to a record $55.0 million.
-
Significant Net Loss Reduction
Net loss improved by 97% to $25.2 million, a substantial reduction from $793.5 million in the prior year period, with net loss per share improving to $(0.24) from $(8.69).
-
Adjusted EBITDA Growth
Adjusted EBITDA increased 19% to $10.7 million, reflecting improved operational efficiency.
-
Strong International Cannabis Growth
International cannabis net revenue accelerated with 73% year-over-year growth, and Canadian adult-use and medical cannabis net revenue combined increased 8%.
auto_awesomeAnalysis
Tilray Brands delivered strong third-quarter fiscal 2026 results, showcasing record net revenue and gross profit, alongside a dramatic 97% reduction in net loss. This significant improvement in profitability, moving from a $793.5 million net loss to $25.2 million, indicates a positive shift in the company's financial health. The robust growth in international cannabis revenue and the reconfirmation of fiscal year 2026 adjusted EBITDA guidance provide further confidence in the company's operational execution and strategic direction. The recent BrewDog acquisition and Carlsberg partnership position Tilray for expanded global reach in the craft beverage market, complementing its core cannabis business.
At the time of this filing, TLRY was trading at $6.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $753.8M. The 52-week trading range was $3.51 to $23.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.